Prazer Therapeutics Inc.
- Headquarters
- Seoul, South Korea
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2026-01-09 | Janssen Pharmaceutica NV | SPiDEM targeted protein degradation platform | Not disclosed | Not disclosed | Not disclosed | Not disclosed |